| 摘要: |
| 目的探讨CD4+、CD8+T淋巴细胞在非小细胞肺癌（NSCLC）术后行辅助放疗患者中的表达情况及其对预后的预测价值。方法选择46例接受辅助放疗的Ⅱ~Ⅲ期NSCLC患者，收集患者的临床资料，应用免疫组化法，检测患者肿瘤组织、间质组织中CD4+、CD8+T淋巴细胞的表达情况。通过单因素与多因素分析，评估T淋巴细胞表达对NSCLC患者3年生存率的影响。结果NSCLC患者的年龄、组织学分化程度以及淋巴结分期与总生存时间相关（均P＜0.05）；肿瘤及间质组织中CD4及CD8表达与患者年龄、性别、病理类型、组织学分化程度及淋巴结分期等临床病理因素均无关（均P＞0.05）；肿瘤组织及间质组织高表达CD4者3年总生存率为52.94%、50.00%，间质组织高表达CD8者3年总生存率为61.11%，均明显高于低表达者（均P＜0.05）；多因素分析显示，肿瘤组织CD4高表达者的HR为0.048（P＜0.01），是NSCLC患者3年总生存率的独立预测因子。结论高表达CD4+T淋巴细胞可作为NSCLC术后患者是否选择辅助放疗的免疫标志物，肿瘤高表达CD4可以获得更好的预后。 |
| 关键词: 非小细胞肺癌 CD4+ 淋巴细胞 CD8+ 淋巴细胞 放疗 预后 |
| DOI：10.12056/j.issn.1006-2785.2018.40.7.2017-2094 |
| 分类号: |
| 基金项目:浙江省自然科学青年基金项目（LQ16H160002）；宁波市自然科学基金（2016A610196） |
|
| CD4 expression shows prognostic value in non-small cell lung cancer with adjuvant radiotherapy |
|
|
|
Ningbo Medical Treatment Center Lihuili Hospital
|
| Abstract: |
| Objective To investigate the expression of CD4 and CD8 T-lymphocytes in non-small cell lung cancer (NSCLC) patients with adjuvant radiotherapy and its prognostic significance. Methods Forty six patients with stage II-III NSCLC who received adjuvant radiotherapy after surgery were enrolled in the study. The expression of CD4 and CD8 T lymphocytes in
lung cancer tissue and stromal tissue were detected by immunohistochemical staining. Results The overall survival of patients was associated with age, gender, and histological differentiation of patients (P ＜0.05). The expression of CD4 and CD8 lymphocytes in lung cancer tissue and stromal tissue were not correlated with age, gender, pathological type, histological differentiation and lymph node metastasis (P ＞0.05). The 3-year overall survival rate of patients with high CD4 expression in tumor, in stromal tissue and high CD8 expression in stromal tissue were 52.94%, 50.00% and 61.11%, which was higher than that in patients with low expression (P＜0.05). Cox analysis showed that high-CD4 expression in cancer tissue was an independent predictor for overall survival (HR=0.048, P＜0.01). Conclusion High CD4+ expression in cancer tissue is associated with higher overall survival for patients with NSCLC receiving adjuvant radiotherapy after surgery. |
| Key words: Non-small-cell lung cancer CD4-Positive Lymphocytes CD8-Positive Lymphocytes Radiotherapy Prognosis |
